🟢 CALC Surges 8.7% as Favorable FDA News, Financing, and Insider Buying Fuel Multi-Day Rally

CALC is trading 8.7% up at $1.12 today, extending its sharp multi-day rally. The sustained speculative momentum is now bolstered by several recent company-specific developments:

• The FDA provided favorable feedback on the Phase 2 KOURAGE trial protocol for its drug Auxora, allowing dosing to resume, announced on June 24, 2026.
• CalciMedica announced a private placement financing of up to approximately $49 million, extending its cash runway, also on June 24, 2026.
• A director made a notable insider purchase of 248,972 shares on June 29, 2026, signaling confidence in the company.